prolaio eVO2peak Module vs iPredict Eye Screening

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Prolaio
VS
by iHealthScreen

AI Verdict

Tool A is designed for cardiovascular research and care, specifically estimating peak oxygen consumption using wearable sensor data. Tool B, while also FDA-cleared and AI-powered, focuses primarily on ophthalmological screening for conditions like AMD and DR, with an additional feature for systemic disease risk prediction including heart attack. Their core functionalities and data inputs are distinct, making them suitable for different clinical applications.

Choose prolaio eVO2peak Module if…

Choose Prolaio eVO2peak Module if your primary objective is to accurately estimate peak oxygen consumption (eVO2peak) for cardiovascular assessment and research, particularly when leveraging longitudinal data from FDA-cleared wearable medical sensors. This tool is ideal for specialists in cardiology, physical medicine & rehab, or sports medicine seeking an adjunctive aid to evaluate cardiac function and fitness over time.

View prolaio eVO2peak Module →

Choose iPredict Eye Screening if…

Choose iPredict Eye Screening if you require a rapid, AI-powered solution for comprehensive screening of multiple ocular diseases, including AMD, Diabetic Retinopathy, and Glaucoma, especially in primary care or high-volume screening environments. This tool is also well-suited for integrating systemic disease risk prediction for conditions like stroke and heart attack into patient evaluations, offering quick results and seamless EHR integration.

View iPredict Eye Screening →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature prolaio eVO2peak Module iPredict Eye Screening
Pricing Unknown Contact for pricing
Deployment Cloud Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps.
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Unknown Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature prolaio eVO2peak Module iPredict Eye Screening
Primary Function Estimates peak oxygen consumption (eVO2peak) using real-world patient data for cardiovascular research and care. AI-powered screening tool for age-related macular degeneration (AMD), Diabetic Retinopathy (DR), and Glaucoma, with risk prediction for systemic diseases.
Company Prolaio iHealthScreen
Key Input Data / Modalities Demographic data, single-lead ECG, and triaxial accelerometry inputs from qualified third-party FDA-cleared wearable medical sensors. Image Analyzer for Retinal Vessel, Retinal Pathology, and OCT Inspector (implied retinal images).
Target Conditions/Diseases Peak oxygen consumption (eVO2peak) estimation for cardiovascular research and care. Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Glaucoma, and risk prediction for stroke and heart attack.
Specialties Cardiology, Physical Medicine & Rehab, Sports Medicine Family Medicine, Internal Medicine, Ophthalmology

Videos

Demos, reviews, and walkthroughs featuring prolaio eVO2peak Module and iPredict Eye Screening.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Prolaio eVO2peak Module processes remote sensor data from qualified third-party wearable medical sensors, suggesting data collection may occur outside a direct clinical encounter. iPredict Eye Screening is designed for quick in-clinic use, with tests completed in less than 5 minutes and reports generated in under 60 seconds, indicating a rapid integration into patient visits.
The Prolaio eVO2peak Module's description does not explicitly mention EHR integration. In contrast, iPredict Eye Screening explicitly offers Electronic Health Record (EHR) Solutions and is designed for integrating with EHR and telemedicine services.
The Prolaio eVO2peak Module applies a locked deep-learning model for eVO2peak estimation, but specific accuracy or sensitivity percentages are not provided in the description. iPredict Eye Screening reports high accuracy, approximately 95% on average, with AMD sensitivity at 86.86% and specificity at 94.13%.
The Prolaio eVO2peak Module is designed for cardiovascular research and care, estimating peak oxygen consumption as an adjunctive aid in clinical evaluation for specialties like Cardiology, Physical Medicine & Rehab, and Sports Medicine. iPredict Eye Screening is an AI-powered screening tool for age-related macular degeneration (AMD) in patients aged 50 years and older, Diabetic Retinopathy (DR), and Glaucoma, also providing risk prediction for systemic diseases like stroke and heart attack, suitable for Family Medicine, Internal Medicine, and Ophthalmology.
The Prolaio eVO2peak Module involves processing remote sensor data and interpreting eVO2peak estimations, which may require familiarity with cardiovascular metrics and data inputs. iPredict Eye Screening is described as easy to operate, non-invasive, and features an advanced touchscreen interface, suggesting a minimal learning curve for clinical staff.
The Prolaio eVO2peak Module enables high-density, longitudinal data collection and leverages real-world patient data and insights for eVO2peak estimation. iPredict Eye Screening offers AI-based screening for multiple conditions and an online health risk prediction system for systemic diseases, which can contribute to ongoing patient monitoring and risk assessment over time.
AI Tool Finder
AI-powered search. Results may not be comprehensive.